Health care is going through dramatic change—but is doing so under some of the dullest names possible. So I’m offering a few alternatives that are more to the point. How about, ‘No-more-bankruptcy care’?
Biomet’s project calls for building renovations and adding 3-D printing and optical scanning technology. The Warsaw-based company would also upgrade an incubation center for surgeons interested in introducing a new product, technology or technique.
For 2014, at least, Obamacare's dreams of expanding individual insurance coverage in Indiana have simply failed. There's no getting around it.
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
Obama’s latest delay of Obamacare insurance rules could sabotage the law’s exchanges. The president must be counting on Republican critics, like Indiana Insurance Commissioner Stephen Robertson, to stop him.
Indiana-based Biomet Group Inc., a closely held maker of orthopedic medical devices, had been publicly traded until 2007 when it was acquired by the group of private equity firms.
Employees, rather than employers, will soon choose their own health insurers—either through the Obamacare exchanges or through private exchanges. Does that mean health insurance brokers, the people who match up employers with insurers, will no longer be needed?
Dow AgroSciences LLC is spending millions of dollars and racking up hundreds of patents as its expands ever deeper in the burgeoning global market for genetically modified crops and pesticides.
Even though the state’s three largest hospital systems–IU Health, St. Vincent Health and Franciscan Alliance–eliminated a combined 2,700 jobs, it created just a blip in the long-term run-up in hospital employment.
The choice for health care providers is binary: either limit patient choice through restricted networks or preserve patient choice by making price transparency real and usable. Hospitals and doctors would be better served by the latter.
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
Even if Gov. Mike Pence and Obama’s health secretary can’t come to terms this weekend, there are ideas bouncing around the state legislature that suggest other ways Indiana could expand coverage to low-income Hoosiers.
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
Rich employer benefits are not always so attractive, sick patients are not always money losers for insurers, and hospitals and doctors are now health care preventers rather than health care providers. This is the bizarre world to which Obamacare has brought us.
The latest enrollment data from the Obamacare exchanges show that three out of four Hoosiers are purchasing decent coverage—not the super high-deductible plans that concerned hospitals.
Fritz French and Richard DiMarchi, the former leaders of Marcadia Biotech, have teamed up to launch the diabetes drug development firm Calibrium LLC.
Ever since World War 2, when employers started using health benefits to compete for workers, the less employees had to pay toward health insurance premiums the more attractive the benefits. But under Obamacare, this axiom will not always be true.
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
Indiana-based Biomet Inc. has agreed to pay a base rate of $200,000 each to hundreds of people who received artificial hips that were later replaced.
The Foundry Investment Fund will join with other investors to provide funding for companies that use Purdue-licensed technology or expertise in human and animal health and plant sciences.
